Shots:
- Orionis Biosciences has entered into a multi-year collaboration with Novartis to discover & design molecular glue drugs for challenging therapeutic targets across multiple disease areas
- As per the deal, the companies will leverage Orionis’s Allo-Glue platform & AI-powered discovery engine to accelerate target & ligase profiling, as well as molecular glue optimization, enabling the discovery of small-molecule glues that modulate disease-relevant targets through induced proximity mechanisms
- Orionis will receive $40M upfront & ~$1.4B in research, development, & commercial milestone payments, along with tiered royalties on net sales of collaboration products
Ref: Businesswire | Image: Orionis & Novartis | Press Release
Related News: Genentech Collaborates with Orionis to Identify and Develop Molecular Glue Therapies for Cancer Targets
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
